ALLOGENEIC UMBILICAL-CORD DERIVED MESENCHYMAL STROMAL CELLS MSC(UC) AS TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): SAFETY AND EARLY CLINICAL/BIOLOGICAL RESULTS FROM A PHASE I-II PROOF-OF-CONCEPT CLINICAL STUDY

间充质干细胞 脐带 医学 临床终点 不利影响 强的松 内科学 临床试验 免疫学 胃肠病学 病理
作者
Dominique Farge,Lucie Biard,B. Weil,Séverine Loisel,Pauline Lansiaux,I. Munia,Virginie Girault,Cyril Charles,Anne‐Sophie Korganow,C. Beuvon,G. Pugnet,Carlotta Cacciatore,N. Abisror,Jean‐Luc Taupin,Audrey Cras,M. Lowdell,Karin Tarte
出处
期刊:Cytotherapy [Elsevier]
卷期号:26 (6): S45-S46
标识
DOI:10.1016/j.jcyt.2024.03.076
摘要

Background & Aim: Background Preclinical studies show Mesenchymal Stromal Cells (MSC) unique immunomodulatory, proangiogenic, and antifibrotic effects. Few clinical data report MSC use to treat Systemic Lupus (SLE) patients (pts) resistant to standard immunosuppressors and biologics, who suffer from high morbidity and increased mortality. Aims To test the safety and preliminary efficacy of a single intravenous injection of allogeneic umbilical cord-derived (UC) MSC in severe SLE. Methods, Results & Conclusion: Methods A prospective, single-center, Bayesian phase I/II study (NCT03562065) enrolled SLE pts (ACR criteria + antinuclear antibodies), aged 18–70 years (yr) with active disease (SELENA-SLEDAI-2K ≥6) at baseline and refractory to >2 immunosuppressive therapies for at least 3 months (M), including Prednisone ≥ 6 mg daily for ≥ 28 days, to receive a single infusion of 2 or 4.106 MSC(UC)/kg obtained from a single UC. Primary endpoint was the rate of treatment-related (TR) severe adverse events (SAE, grade ≥ 3) in the first 10 days post-MSC(UC) infusion. Secondary endpoints were adequacy of MSC(UC) production, all AE, clinical, HrQol and immune responses at M1 and quarterly for 1 yr post-infusion. Results From Sept 2019 to Feb 2023, 8 (7 female) pts, median age 35 [IQR 27-60] yrs after 12 [6-21] yrs SLE duration, were included with PGA 2 [1.5-2], SELENA-SLEDAI-2K 11.5 [8-14.2], BILAG A (50%), B (38%) or C (12%) and SLICC-ACR 1.5 [0-2.8] prior MSC(UC) infusion (median dose 2 [IQR 2-4]x106/kg). All pts received ≥2.106/kg MSC(UC) (5 assigned to 2.106/kg, 3 to 4.106/kg) with 1 batch released at lower than expected target dose. No SAE and 3 infusion-related AE (2 grade 1, 1 grade 2) in 2 pts occurred in the first 10 days. After 12.4 (min 9.6-max 13) months of follow-up, there were no TR SAE and 3 non-TR SAE after relapse in 1 pt. Improved clinical status (Table) in 7/8 pts at M3 persisted over 1 yr with 2 major and 2 partial clinical responses at M12. Donor-specific anti-HLA antibodies developed de novo in 1 pt at M3. While circulating T, B, NK and monocytes were unmodified by MSC(UC), CD24hiCD38hi transitional and CD27posCD38neg/loCD24hi memory B-cells frequencies, i.e. regulatory B-cell subsets, increased significantly and transiently at M1. Conclusion A single infusion of MSC(UC) was safe in 8 severe SLE pts. This proof of concept study showed clinical improvement. Placebo-controlled trials are needed to confirm clinical efficacy and explore the role of B-cell modifications in clinical benefit. Preclinical studies show Mesenchymal Stromal Cells (MSC) unique immunomodulatory, proangiogenic, and antifibrotic effects. Few clinical data report MSC use to treat Systemic Lupus (SLE) patients (pts) resistant to standard immunosuppressors and biologics, who suffer from high morbidity and increased mortality. To test the safety and preliminary efficacy of a single intravenous injection of allogeneic umbilical cord-derived (UC) MSC in severe SLE. A prospective, single-center, Bayesian phase I/II study (NCT03562065) enrolled SLE pts (ACR criteria + antinuclear antibodies), aged 18–70 years (yr) with active disease (SELENA-SLEDAI-2K ≥6) at baseline and refractory to >2 immunosuppressive therapies for at least 3 months (M), including Prednisone ≥ 6 mg daily for ≥ 28 days, to receive a single infusion of 2 or 4.106 MSC(UC)/kg obtained from a single UC. Primary endpoint was the rate of treatment-related (TR) severe adverse events (SAE, grade ≥ 3) in the first 10 days post-MSC(UC) infusion. Secondary endpoints were adequacy of MSC(UC) production, all AE, clinical, HrQol and immune responses at M1 and quarterly for 1 yr post-infusion.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
chrislignin完成签到,获得积分10
2秒前
酷波zai完成签到 ,获得积分10
6秒前
ICY完成签到,获得积分10
10秒前
希望天下0贩的0应助orange采纳,获得10
11秒前
今后应助每天都火大采纳,获得10
15秒前
小鱼完成签到,获得积分10
16秒前
16秒前
ke研白完成签到,获得积分10
17秒前
Sylvia完成签到 ,获得积分10
19秒前
21秒前
默默访风发布了新的文献求助10
21秒前
VDC发布了新的文献求助10
23秒前
包容丹云完成签到,获得积分10
24秒前
子陇完成签到,获得积分10
24秒前
Bismarck完成签到,获得积分10
25秒前
余增辉完成签到 ,获得积分10
25秒前
26秒前
默默访风完成签到,获得积分10
28秒前
ZZZ完成签到,获得积分10
30秒前
zeng123发布了新的文献求助10
33秒前
自由冬亦完成签到,获得积分10
34秒前
妮妮完成签到,获得积分10
34秒前
田様应助ZDZ采纳,获得10
35秒前
朱玉完成签到,获得积分10
39秒前
mmlb发布了新的文献求助10
44秒前
ZDZ完成签到,获得积分20
47秒前
布熙哆完成签到,获得积分10
48秒前
机智柚子完成签到,获得积分10
48秒前
秋迎夏完成签到,获得积分0
48秒前
48秒前
51秒前
怕孤单的听寒完成签到,获得积分10
53秒前
55秒前
56秒前
zeng123完成签到,获得积分20
59秒前
1分钟前
吉吉国王完成签到 ,获得积分10
1分钟前
谨慎的豆芽完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137664
求助须知:如何正确求助?哪些是违规求助? 2788576
关于积分的说明 7787679
捐赠科研通 2444950
什么是DOI,文献DOI怎么找? 1300139
科研通“疑难数据库(出版商)”最低求助积分说明 625814
版权声明 601023